0001654954-21-006925.txt : 20210615
0001654954-21-006925.hdr.sgml : 20210615
20210615163424
ACCESSION NUMBER: 0001654954-21-006925
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210610
FILED AS OF DATE: 20210615
DATE AS OF CHANGE: 20210615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doogan Declan
CENTRAL INDEX KEY: 0001704234
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34600
FILM NUMBER: 211018931
MAIL ADDRESS:
STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP
STREET 2: 234 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0000034956
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262593535
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE COPLEY PARKWAY
STREET 2: SUITE 490
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
BUSINESS PHONE: 919-806-4414
MAIL ADDRESS:
STREET 1: ONE COPLEY PARKWAY
STREET 2: SUITE 490
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
FORMER COMPANY:
FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC.
DATE OF NAME CHANGE: 20080703
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: SINEQUANON CORP
DATE OF NAME CHANGE: 19901219
4
1
section16.xml
PRIMARY DOCUMENT
X0306
4
2021-06-10
0000034956
TENAX THERAPEUTICS, INC.
TENX
0001704234
Doogan Declan
C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP
234 CHURCH STREET
NEW HAVEN
CT
06510
true
true
Common Stock
2021-06-11
4
M
false
3070000
A
3637871
D
Stock Option (right to buy)
2.00
2021-06-10
4
A
false
6250
0
A
2022-06-10
2031-06-10
Common Stock
6250
6250
D
Series B Preferred Stock
2021-06-11
4
M
false
3070
D
2021-06-11
2021-06-11
Common Stock
3070000
0
D
On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021.
As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction.
/s/ Declan Doogan
2021-06-15